Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

ABSTRACT Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and effective vaccines against MERS. We have previously demonstrated that a receptor-binding domain (RBD) fragment containing residues 377–588 of MERS-coronavirus (MERS-CoV) spike protein is a critical neutralizing domain and an important vaccine target. Nevertheless, its optimal immunogen dosage and immunization interval, key factors for human-used vaccines that induce protective immunity, have never been investigated. In this study, we optimized these criteria using a recombinant MERS-CoV RBD protein fused with Fc (S377–588-Fc) and utilized the optimal immunization schedule to evaluate the protective efficacy of RBD against MERS-CoV infection in human dipeptidyl peptidase 4 transgenic (hDPP4-Tg) mice. Compared with one dose and 2 doses at 1-, 2-, and 3-week intervals, a regimen of 2 doses of this protein separated by an interval of 4 weeks induced the strongest antibody response and neutralizing antibodies against MERS-CoV infection, and maintained at a high level during the detection period. Notably, RBD protein at the optimal dosage and interval protected hDPP4-Tg mice against lethal MERS-CoV challenge, and the protection was positively correlated with serum neutralizing antibodies. Taken together, the optimal immunogen dosage and immunization interval identified in this study will provide useful guidelines for further development of MERS-CoV RBD-based vaccines for human use.

[1]  G. Gaus,et al.  Searching for the Ideal , 2017 .

[2]  S. Perlman,et al.  Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines , 2016, Nature Communications.

[3]  Yufei Wang,et al.  Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants , 2016, Journal of Virology.

[4]  P. van Damme,et al.  A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly. , 2016, Vaccine.

[5]  Yufei Wang,et al.  A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection , 2016, Virology.

[6]  Nam-Hyuk Cho,et al.  Outbreaks of Middle East Respiratory Syndrome in Two Hospitals Initiated by a Single Patient in Daejeon, South Korea , 2016, Infection & chemotherapy.

[7]  J. Segalés,et al.  An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels , 2016, Science.

[8]  Shibo Jiang,et al.  Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus , 2015, PloS one.

[9]  Lu Lu,et al.  Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease , 2015, Journal of Virology.

[10]  S. Black.  Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults. , 2015, Vaccine.

[11]  J. Mascola,et al.  Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults , 2015, PloS one.

[12]  Shibo Jiang,et al.  Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus , 2015, Human vaccines & immunotherapeutics.

[13]  Sujin Lee,et al.  Recent Advances of Vaccine Adjuvants for Infectious Diseases , 2015, Immune network.

[14]  Shibo Jiang,et al.  Receptor Usage and Cell Entry of Porcine Epidemic Diarrhea Coronavirus , 2015, Journal of Virology.

[15]  S. Perlman,et al.  Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus , 2015, Cellular and Molecular Immunology.

[16]  Fang Li,et al.  Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies , 2014, Journal of Virology.

[17]  Christian Drosten,et al.  Evidence for camel-to-human transmission of MERS coronavirus. , 2014, The New England journal of medicine.

[18]  Shibo Jiang,et al.  Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design , 2014, Vaccine.

[19]  R. Liddington,et al.  Effects of Human Anti-Spike Protein Receptor Binding Domain Antibodies on Severe Acute Respiratory Syndrome Coronavirus Neutralization Escape and Fitness , 2014, Journal of Virology.

[20]  Yan Li,et al.  Bat Origins of MERS-CoV Supported by Bat Coronavirus HKU4 Usage of Human Receptor CD26 , 2014, Cell Host & Microbe.

[21]  Fekri Abroug,et al.  Family Cluster of Middle East Respiratory Syndrome Coronavirus Infections, Tunisia, 2013 , 2014, Emerging infectious diseases.

[22]  Jerome H. Kim,et al.  Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses. , 2014, The Journal of infectious diseases.

[23]  R. Baric,et al.  Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus , 2014, Proceedings of the National Academy of Sciences.

[24]  S. S. Sohrab,et al.  Detection of the Middle East Respiratory Syndrome Coronavirus Genome in an Air Sample Originating from a Camel Barn Owned by an Infected Patient , 2014, mBio.

[25]  S. El-Kafrawy,et al.  Evidence for camel-to-human transmission of MERS coronavirus. , 2014, The New England journal of medicine.

[26]  William B. Karesh,et al.  Middle East Respiratory Syndrome Coronavirus Quasispecies That Include Homologues of Human Isolates Revealed through Whole-Genome Analysis and Virus Cultured from Dromedary Camels in Saudi Arabia , 2014, mBio.

[27]  Shibo Jiang,et al.  Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.

[28]  Shibo Jiang,et al.  Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines , 2014, Vaccine.

[29]  Lu Lu,et al.  Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.

[30]  Shibo Jiang,et al.  A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines , 2013, PloS one.

[31]  Amit Kapoor,et al.  Middle East Respiratory Syndrome Coronavirus in Bats, Saudi Arabia , 2013, Emerging infectious diseases.

[32]  George F. Gao,et al.  Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[33]  Shibo Jiang,et al.  A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV , 2013, Virology Journal.

[34]  Z. Memish,et al.  A family cluster of Middle East Respiratory Syndrome Coronavirus infections related to a likely unrecognized asymptomatic or mild case , 2013, International Journal of Infectious Diseases.

[35]  D. Cummings,et al.  Hospital outbreak of Middle East respiratory syndrome coronavirus. , 2013, The New England journal of medicine.

[36]  Linqi Zhang,et al.  Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 , 2013, Cell Research.

[37]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[38]  Ziad A Memish,et al.  Family cluster of Middle East respiratory syndrome coronavirus infections. , 2013, The New England journal of medicine.

[39]  B. Bosch,et al.  The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies , 2013, Journal of Virology.

[40]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[41]  Shibo Jiang,et al.  A Critical HA1 Neutralizing Domain of H5N1 Influenza in an Optimal Conformation Induces Strong Cross-Protection , 2013, PloS one.

[42]  Giuseppe Del Giudice,et al.  The history of MF59® adjuvant: a phoenix that arose from the ashes , 2013, Expert review of vaccines.

[43]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[44]  F. Buonaguro,et al.  Effects of adjuvants on IgG subclasses elicited by virus-like Particles , 2012, Journal of Translational Medicine.

[45]  Shibo Jiang,et al.  Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients , 2010, Virology Journal.

[46]  Hong-xia Yu,et al.  Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies , 2010, Biochemical and Biophysical Research Communications.

[47]  R. Gasparini,et al.  Impact of prior or concomitant seasonal influenza vaccination on MF59‐adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects , 2010, International journal of clinical practice.

[48]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[49]  P. Libby,et al.  Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. , 2008, The American journal of pathology.

[50]  Steven Riley,et al.  Optimizing the Dose of Pre-Pandemic Influenza Vaccines to Reduce the Infection Attack Rate , 2007, PLoS medicine.

[51]  Yan Guo,et al.  Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model , 2006, Vaccine.

[52]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[53]  K. Yuen,et al.  Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines , 2006, Virology.

[54]  A. Enk,et al.  A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr) , 2005, Cancer Immunology, Immunotherapy.

[55]  L. Levine,et al.  Tetanus toxoid: what determines reaction proneness? , 1981, The Journal of infectious diseases.

[56]  L. Levine,et al.  Excessive use of tetanus toxoid boosters. , 1967, JAMA.

[57]  Shibo,et al.  Recombinant receptor-binding domains of multiple MERS-coronaviruses induce cross-neutralizing antibodies against divergent human and camel MERS-coronaviruses and antibody-escape mutants , 2016 .

[58]  FRCP W. J. MacLennan MD,et al.  The Elderly , 1984, Treatment in Clinical Medicine.